samedan logo
 
 
 
spacer
home > ebr > spring 2003 > biotech's northern alliance gaining ground
PUBLICATIONS
European Biopharmaceutical Review

Biotech's Northern Alliance Gaining Ground

Denmark and Sweden haven't always got along - the two countries spent much of the 17th Century fighting it out to enlarge their kingdoms. One particularly cold winter, when the narrow stretch of water between the two countries (the Øresund) froze up, the Swedes seized the moment and sent armed horsemen across the ice to pay an unfriendly visit.

Things have settled down since then - the Øresund was bridged three years ago and no armies have marched across it yet. In fact, the bridge reflects a new understanding between the two old foes that they are better off joining forces, not least to attract international business. Today, two bi-national investment groups, Copenhagen Capacity and Position Skåne, are busy promoting greater Copenhagen and Sweden's Skåne region as a single enterprise zone. They have dubbed the region 'Medicon Valley' to attract the interest of one of their prime industry targets: life science.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Hal Grey, Freelance Journalist

Hal Grey is an American freelance journalist and Marketing Consultant living in Copenhagen. He has worked for several Danish firms in international marketing and communications positions, and in advertising and public relations in the United States.

He holds a Master's degree in Journalism from Columbia University, New York.

spacer
Hal Grey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement